Treatment with single-agent carfilzomib achieved durable responses in patients with relapsed/refractory multiple myeloma whose disease had relapsed after they received all available therapies (including bortezomib and immunomodulatory agents), suggesting that this agent has the potential to offer substantial clinical benefit. The data was presented at the 52nd American Society of Hematology Annual Meeting and Exposition.
Sign in with your MPR account
Keep me signed in Forgot your password?
REGISTER FOR FREE WITH A MPR ACCOUNT
Enter your MPR registration email address to receive a new password.